Pfizer UK will provide subscription access to the Ledidi Core platform, a cloud-based service which, is an all-in-one platform for collecting, structuring, analysing and visualising data in a GDPR compliant platform with a built in mechanism of collaboration. The platform allows for the creation of registries, research projects and multi-centre collaborations with real time statistical analytics. The sharing of data between collaborators is controlled by the lead Trust and the platform does not limit the number of projects/registries/collaborations.
Below is a selection of institutions currently using the Ledidi Core platform to run local, national, and international registries:
European Polyp Surveillance study; Spain, Norway, Netherlands, Sweden, Poland, Denmark, Austria, and Portugal
Clatterbridge Cancer Centre NHS Foundation Trust
Weill Cornell Medical College, Cornell University, New York, USA
The International Liver Database Consortium. Boston University, Boston, USA
The Norwegian NevroCovid Study
The Pfizer donation will consist of two options:
Access to the Ledidi Core platform for 36 months
The subscription will start once the HCP/Trust has created their account with Ledidi
Ledidi can offer personalised onboarding of the users, including support in data privacy support with trust IT, within a reasonable scope
Ledidi will ensure that they continue to provide support for the platform for the duration of the 36 months
Pfizer will provide a one-off donation of £2,000 to help support the facilitation and data entry onto the site
Neither Pfizer nor Ledidi will have access to or be privy to any data entered onto the site, the trust remains the data owners and all anonymised patient information remains the property of the trust. Any sharing of data by the trust is through their own collaborations either within or outside of the platform and Ledidi is required to maintain adherence to data privacy laws.
All NHS hospitals within the UK treating breast cancer are permitted to apply for this service donation grant. Eighty subscriptions in total are available and NHS trusts will be selected to receive this donation on a first-come, first-served basis and based on the below criteria:
Treating breast cancer patients
At least one member of the hospital team dedicated to helping facilitate the audit including ensuring appropriate local data protection and IT facilitation
NHS hospital shows commitment to completing audit in a timely manner
NHS hospital expresses intent to share best practice via local or national publication/congress presentation
For further information on the data privacy and security of the Ledidi Core platform please refer to the following links. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. Pfizer accepts no responsibility for the content or services of the linked site.
All applications will be reviewed in order of application date and time on a first-come, first-served basis. Once all grant funding and subscriptions has been allocated then the application portal will close. If a large number of applications are received all at once then the application portal may close until the backlog of applications is reviewed or until all grants are allocated, whichever occurs first.
All applications will be reviewed by an internal Pfizer medical review panel. Once you have submitted a request, we will also share further information regarding Ledidi Core. Additional clarification during the review period may be requested. All applicants will be notified via email regarding the outcome of their request, upon completion of the internal review process.
If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. In the event of a successful application, core terms of the agreement will be provided at a later date. Disclosure of this Pfizer funded grant will be required by each recipient hospital.